Nanjing Well Pharmaceutical Group Co.,Ltd. (SHSE:603351) agreed to acquire 13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong for CNY0 on July 28, 2023. Nanjing Well Pharmaceutical Group Co.,Ltd. (SHSE:603351) signed an agreement to acquire 13% stake in Nanjing Xingwei Biotechnology Co., Ltd. from Wu Renrong, Gao Zhengsong, Chen Xinguo, Tang Qunsong, Shen Jiusi, Wu Rongwen, Hong Shilin, Zou Jianguo, Wang Fuqiu and Zhou Chong for CNY0 in August 2023. On July 28, 2023, the 3rd session of the Nanjing Well Pharmaceutical Group Co.,Ltd. (SHSE:603351) 3rd directorate and the 3rd session of the Nanjing Well Pharmaceutical Group Co.,Ltd. (SHSE:603351) 3rd supervisory board approved the proposal on the signing of the cooperation framework agreement?s supplemental agreement and the acquisition of minority equity in holding subsidiary.